Fraunhofer IZI in Leipzig, led by Prof. Dr. Dr. Ulrike Köhl, Director of the Institute and Professor of Immuno-Oncology at the University of Leipzig, is the academic co-coordinator of EASYGEN Consortium. With more than 4,000 released cell and gene therapy products, including over 600 CAR-T cell products, Fraunhofer IZI brings outstanding expertise in process development, manufacturing and technological innovation.Together with its branch site in Würzburg, headed by Prof. Dr. Michael Hudecek, Professor of Cellular Immunotherapy at the University of Würzburg, the team drives the development of next-generation CAR-T technologies. Their focus lies on point-of-care manufacturing, automation, artificial intelligence, and modular process platforms to make production and access more efficient.Fraunhofer IZI also contributes its leading expertise in non-viral gene transfer, particularly in transposon technology, to simplify and reduce the cost of manufacturing processes and accelerate patient access across Europe.